Article Title: The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma
Author: Sumit Agarwal, Shikha Saini, Deepak Parashar, Archana Verma, Abhilasha Sinha, Nirmala Jagadish, Aruna Batra, Sushma Suri, Anju Gupta, Abdul S. Ansari, Nirmal Kumar Lohiya and Anil Suri
Journal: OncoImmunology
Bibliometrics: Volume 2, Issue 5, pages e24270
DOI: 10.4161/onci.24270
In the published version of Figure 4B, the Authors inadvertently duplicated Lane 4 (displaying AKAP4-immunoreactive bands in ovarian carcinoma patients indicative of AKAP4-specific humoral responses in representative Stage II patients) and Lane 2 (displaying polyclonal anti-AKAP4 antibody showing AKAP4 immunoreactivity). The corrected Figure 4B is enclosed. The figure legend is correct as published and is shown for reference below. This error has no impact on the interpretation of the results, nor does it influence the conclusions of the work.
Figure 4.
Humoral responses against AKAP 4 in ovarian carcinoma patients. (A) Figure Humoral responses against AKAP 4 in ovarian cancer specimens obtained from Stage I, Stage II, Stage III and Stage IV patients. X represents the cut-off value (calculated as the mean of antibody titers detected in healthy donors + 2SD) above which all specimens were considered as positive. (B) Immunoblotting experiments were performed to confirm anti-AKAP 4 humoral responses and the specificity of circulating anti-AKAP 4 antibodies was validated by neutralization experiments. Lane 1, coomassie brilliant blue stained purified recombinant AKAP 4 protein; Lane 2, polyclonal anti-AKAP 4 antibody showing AKAP 4 immunoreactivity; Lane 3–6, AKAP 4-immunoreactive bands indicative of AKAP –specific humoral responses in representative Stage I, Stage II, Stage III and Stage IV patients; Lane 7, absence of anti-AKAP 4 humoral responses in the serum of a healthy donor; Lane 8, absence of AKAP 4-immunoreactive bands upon the pre-incubation of the patient’s serum with 15 μg/mL recombinant AKAP 4
The authors apologize for any inconvenience that may have been caused.